Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -0.10% | 345.40 | 0.0% | $4305.01m | |
| BNTX | BioNTech SE | 1.74% | 297.49 | 0.0% | $826.27m | |
| NVAX | Novavax, Inc. | -1.10% | 133.50 | 79.4% | $750.42m | |
| AMGN | Amgen, Inc. | 0.00% | 208.68 | 1.4% | $526.19m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.00% | 592.15 | 2.7% | $478.99m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | 0.00% | 6.21 | 0.7% | $434.10m | |
| GILD | Gilead Sciences, Inc. | -0.66% | 67.28 | 1.0% | $395.23m | |
| CCXI | ChemoCentryx, Inc. | -0.83% | 33.44 | 2.9% | $383.29m | |
| ILMN | Illumina, Inc. | 0.00% | 417.19 | 3.3% | $357.19m | |
| XLRN | Acceleron Pharma, Inc. | 0.00% | 173.78 | 5.3% | $335.39m | |
| OCGN | Ocugen, Inc. | -0.44% | 9.11 | 0.0% | $302.02m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 0.23% | 184.50 | 1.9% | $274.69m | |
| BIIB | Biogen, Inc. | 0.00% | 271.12 | 1.8% | $271.81m | |
| XENE | Xenon Pharmaceuticals, Inc. | 0.00% | 30.57 | 0.4% | $164.85m | |
| CRSP | CRISPR Therapeutics AG | 0.06% | 95.12 | 0.6% | $159.17m |
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company. It engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.